Evidence-based medicine accepts the treatment of individuals with DN by the control of high blood sugar and hypertension, and therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), which can slow or halt the progression of diabetic renal disease in early stages. This evidence concerns the gene ACE and liver dysplastic nodule.